Amarin Provides Update on VASCEPA® (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong KongGlobeNewsWire • 02/09/21
Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk ReductionGlobeNewsWire • 01/29/21
Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance ProviderGlobeNewsWire • 01/26/21
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular DiseasesGlobeNewsWire • 01/21/21
Amarin Corporation PLC (AMRN) CEO John Thero Presents at the 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)Seeking Alpha • 01/13/21
With Alexion Off the Board, Amarin and Biomarin Are Attractive Acquisition TargetsGuruFocus • 12/24/20
Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical ResultsGlobeNewsWire • 12/14/20
Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020GlobeNewsWire • 12/13/20
VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessions 2020GlobeNewsWire • 12/07/20
Amarin Corporation plc (AMRN) CEO John Thero Presents at Piper Sandler 32nd Annual Virtual Healthcare Conference Call - (Transcript)Seeking Alpha • 12/02/20
Amarin to Present at Piper Sandler's 32nd Annual Healthcare Conference (Virtual)GlobeNewsWire • 11/24/20